title: Clozapine: is now the time for more clinicians to adopt this orphan?
abstract: Although many patients with schizophrenia fail to respond adequately to trials of 2 or more antipsychotics, utilization of clozapine for these patients remains low, despite recommendations for its use by accepted treatment guidelines. Some experts estimate that 5-10 times more patients could benefit from clozapine than who are now receiving it. Learning how to manage the unique side effect profile of clozapine can potentially remove barriers to prescribing this agent and thus unlock its unique therapeutic efficacy for more patients.
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Stahl
mesh_terms: D000380:Agranulocytosis / Q000139:chemically induced; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003024:Clozapine / Q000627:therapeutic use*; D003248:Constipation / Q000139:chemically induced; D003920:Diabetes Mellitus / Q000139:chemically induced; D004802:Eosinophilia / Q000139:chemically induced; D006801:Humans; D009205:Myocarditis / Q000139:chemically induced; D009459:Neuroleptic Malignant Syndrome; D009503:Neutropenia / Q000139:chemically induced; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D012559:Schizophrenia / Q000188:drug therapy*; D012798:Sialorrhea / Q000139:chemically induced; D013610:Tachycardia / Q000139:chemically induced; D015430:Weight Gain
chemical_list: D014150:Antipsychotic Agents; D003024:Clozapine